Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871415 | 0.91 | IDO1 (0.40) | IDO1P2RX7HTTCHRM1MTNR1A | |
| SCHEMBL27889535 | 0.91 | P2RX7 (0.39) | IDO1P2RX7CHRM1CNR1CNR2 | |
| SCHEMBL1988580 | 0.90 | CHRM1 (0.43) | P2RX7CHRM1CNR1CNR2PDE2A | |
| SCHEMBL10300769 | 0.90 | P2RX7 (0.38) | IDO1P2RX7CHRM1CNR1CNR2 | |
| SCHEMBL6870739 | 0.89 | HTT (0.38) | IDO1HTTCHRM1CNR1CNR2 | |
| SCHEMBL6871390 | 0.88 | CHRM1 (0.42) | IDO1P2RX7HTTCHRM1CNR1 | |
| SCHEMBL6870112 | 0.88 | P2RX7 (0.41) | IDO1P2RX7HTTIL1B | |
| SCHEMBL1276193 | 0.87 | CNR2 (0.40) | IDO1HTTCHRM1CNR1CNR2 | |
| SCHEMBL1275611 | 0.85 | IDO1 (0.39) | IDO1P2RX7CHRM1CNR1CNR2 | |
| SCHEMBL6870062 | 0.84 | P2RX7 (0.41) | IDO1P2RX7HTTCHRM1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367812-B1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4TRIFLUOROMETHOXY-1H-INDOL-3-YL]METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| EP-2367812-B1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4TRIFLUOROMETHOXY-1H-INDOL-3-YL]METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| US-8497379-B2 | Method and intermediates for the preparation of 2,2,2-trifluoro-N-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride | SANOFI (FR) | 2013-07-30 | — | — | US | disclosed |
| US-8497379-B2 | Method and intermediates for the preparation of 2,2,2-trifluoro-N-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride | SANOFI (FR) | 2013-07-30 | — | — | US | disclosed |
| US-8497379-B2 | Method and intermediates for the preparation of 2,2,2-trifluoro-N-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride | SANOFI (FR) | 2013-07-30 | — | — | US | disclosed |
| EP-2538942-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309790-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2012-12-06 | — | — | US | disclosed |
| US-20120309790-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2012-12-06 | — | — | US | disclosed |
| US-20120309790-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2012-12-06 | — | — | US | disclosed |
| US-20120283445-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI (FR) | 2012-11-08 | — | — | US | disclosed |
| WO-2011106334-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106334-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2011-09-01 | — | — | WO | disclosed |
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| WO-2011079103-A1 | SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011078983-A1 | TREATMENT FOR INFLAMMATORY BOWEL DISEASE | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011078983-A1 | TREATMENT FOR INFLAMMATORY BOWEL DISEASE | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010022196-A2 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022196-A2 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | CMA1, TPSAB1, TPSB2 | IDO1 11/4885P2RX7 1022/4885HTT 3181/4885 |
| US-20120283445-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | CMA1, TPSAB1, TPSB2 | IDO1 11/4885P2RX7 1022/4885HTT 3181/4885 |
| US-20120309790-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | TSLP, CMA1, TPSG1 | IDO1 239/4885P2RX7 1608/4885HTT 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.